Q32 Bio Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
4analysts covering
Monitoring Framework
Key Performance Indicators
Severity of Alopecia Tool (SALT) Score Reduction Quarterly18.0Target: 35.3% mean reduction in SALT score
Proportion of Patients Achieving SALT ≤20 Quarterly40.0Target: Clinically meaningful proportion of patients achieving SALT ≤20 at Week 36
Cash Runway (Years) Quarterly2.0Target: Sufficient to fund operations into the first half of 2028
Watch Items
- SIGNAL-AA Phase 2a Part B 36-Week Topline Data ReadoutTrigger: Topline efficacy and safety results for bempikibart in severe and very severe alopecia areataAction: Evaluate clinical efficacy (SALT score improvements) and safety profile to determine advancement into pivotal Phase 3 trials
- Strategic Options for Tissue-Targeted Complement Platform (including ADX-096)Trigger: Execution of out-licensing, sale, or partnership agreementAction: Assess non-dilutive funding terms and potential milestone structures to further extend cash runway
- Milestone Payments from Akebia Therapeutics for ADX-097Trigger: Receipt of $2.0 million near-term milestone and progress toward $580 million in additional milestonesAction: Monitor Akebia's development progress of ADX-097 and verify cash inflows
Research as of 20 Jun 2026